Induction of T cell dependent acquired immunity in syngeneic mice by the combined expression of interleukin-4 and granulocyte macrophage-colony stimulating factor gene in murine colon carcinoma cells

Anticancer Research

Volumn 18, Issue 3 A, 1998, Pages 1453-1456

  Tasaki, Kentaro ^a,b   Gunji, Yoshio ^b   Matsubara, Hisahiro ^b   Takenaga, Keizo ^b,c   Suzuki, Takao ^b   Asano, Takehide ^b   Ochiai, Takenori ^b   Isono, Kaichi ^b   Kouzu, Teruo ^b,c   Sakiyama, Shigeru ^d   Tagawa, Masatoshi ^a,d  

^a Division of Pathology   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c Division of Chemotherapy   (Japan)

^d CHIBA CANCER CENTER   (Japan)

Author keywords

Antitumor immunity; Colon cancer; Gene therapy; Granulocyte macrophage colony stimulating factor; Interleukin 4

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER REGRESSION; COLON CARCINOMA; CONTROLLED STUDY; CYTOKINE RELEASE; GENE EXPRESSION; GENETIC TRANSDUCTION; HOST RESISTANCE; IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR CELL;

EID: 15144349623     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Tepper RI and Mulé JJ: Experimental and clinical studies of cytokinc gene-modified tumor cells. Hum Gene Ther 5: 153-164, 1994.
2. McBride WH, Economou JS, Syljuasen RG, Parrish C, Hackman D, Latham V, Chiang CS and Dougherty GJ: The effects of cytokine gene transfer into tumors on host cell infiltration and regression. Anticancer Res 16: 1139-1143, 1996.
3. Cignetti A, Guarini A, Carbone A, Forni M, Cronin K, Forni G, Ganshacher B and Foa R: Transduction of the IL2 gene into human acute leukemia cells: induction of tumor rejection without modifying cell proliferation and IL2 receptor expression. J Natl Cancer Inst 86: 785-791, 1994.
4. Fakhrai H, Shawler DL, Gjerset R, Naviaux RK, Koziol J, Royston I and Sobal RE: Cytokine gene therapy with interleukin-2-transduced fibroblast: effect of IL-2 dose on anti-tumor immunity. Hum Gene Ther 6: 591-601, 1995.
5. Herrmann F, Cannistra SA, Levine H and Griffin JD: Expression of interleukin 2 receptors and binding of interleukin 2 by gamma interferon-induced human leukemic and normal monocytic cells. J Exp Med 162: 1111-1116, 1985.
6. Tigges MA, Casey LS and Koshland ME: Mechanism of interleukin-2 signaling: mediation of different outcomes by a single receptor and transduction pathway. Science 243: 781-786, 1989.
7. Sobol RE: Injection of colon carcinoma patients with autologous irradiated tumor cells and fibroblasts genetically modified to secrete interleukin-2 (IL-2):a phase I study. Hum Gene Ther 6: 195-204, 1995.
8. Stingel G: Phase I study to the immunotherapy of metastatic malignant melanoma by a cancer vaccine consisting of autologous cancer cells transduced with the human IL-2 gene. Hum Gene Ther 7: 551-563, 1996.
9. Tepper RI, Coffman RL and Leder P: An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science 257: 548-551, 1992.
10. Wei MX, Tamiya T, Hurford RK Jr, Boviatsis EJ, Tepper RI and Chiocca EA: Enhancement of interleukin-4-mediated tumor regression in athymic mice by in situ retroviral gene transfer. Hum Gene Ther 6: 437-443, 1995.
11. Ju DW, Cao X and Acres B: Intratumoral injection of GM-CSF gene encoded recombinant vaccina virus elicits potent antitumor response in a murine melanoma model. Cancer Gene Ther 4: 139-144, 1997.
12. Lee C-T, Wu S, Ciernik F, Chen H, Nadaf-Rahrov S, Gabrilovich D and Carbone DP: Genetic immunotherapy of established tumors with adenovirus-murine granulocyte-macrophage colony-stimulating factor. Hum Gene Ther 8: 187-193, 1997.
13. Gunji Y, Tagawa M, Matsubara H, Takenaga K, Shimada H, Kondo F, Suzuki T, Nakajima K, Sugaya M, Asano T, Ochiai T, Isono K, Kageyama H, Nakamura Y and Sakiyama S: Antitumor effect of murine colon carcinoma cells retrovirally transduced with interleukin-4 and granulocyte macrophage-colony stimulating factor gene. Oncology 54: 69-73, 1997.
14. Corbett TH, Grinswold DP Jr, Roberts BJ, Peckham JC and Schabel FM Jr: Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res 35: 2434-2439, 1975.
15. Brattain MG, Strobel-Stevens J, Fine D, Webb M and Sarrif AM: Establishment of mouse colonic carcinoma cell lines with different metastatic properties. Cancer Res 40: 2142-2146, 1980.
16. Miller AD and Rosman GJ: Improved retroviral vectors for gene transfer and expression. BioTechniques 7: 980-990, 1989.
17. Lee F, Yokota T, Otuka T, Meyerson P, Villaret D, Coffman R, Mosmann T, Rennick D, Roehm N, Smith C, Zlotnik A and Arai K-I: Isolation and characterization of a mouse interleukin cDNA clone that expresses B-cell stimulatory factor 1 activities and T-cell- and mast-cell-stimulating activities. Pro Natl Acad Sei USA 83: 2061-2065, 1986.
18. Miyatake S, Otsuka T, Yokota T, Lee F and Arai K-I: Structure of the chromosomal gene for granulocyte-macrophage colony stimulating factor: comparison of the mouse and human genes. EMBO J 4: 2561-2568, 1985.
19. Wakimoto H, Abe J, Tsunoda R, Aoyagi M, Hirakawa K and Hamada H: Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin-4. Cancer Res 56: 1828-1833, 1996.
20. Poppin BA, Rosenstein M, Jacob WF, Chiang Y and Lotze MT: Local IL-4 delivery enhances immune reactivity to murine tumors: gene therapy in combination with IL-2. Cancer Gene Ther 1: 35-42, 1994.
21. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D and Mulligan RC: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sei USA 90: 3539-3543, 1993.
22. Yu JS, Burwich JA, Dranoff G and Breakefield XO: Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells. Hum Gene Ther 8: 1065-1072, 1997.
23. Sallusto F and Lanzavecchia A: Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and down-regulated by tumor necrosis factor α. J Exp Med 179: 1109-1118, 1994.
24. Mitra RS, Judge TA, Nestle FO, Turka LA and Nickoloff BJ: Psoriatic skin-derived dendritic cell function is inhibited by exogenous IL-10. J Immunol 154: 2668-2677, 1995.
25. Parney IF, Petruk KC, Zhang C, Farr-Jones M, Sykes DB and Chang L-J: Granulocyte-macrophage colony-stimulating factor and B7-2 combination immunogene therapy in an allogeneic hu-PBL-scid/beige mouse-human glioblastoma multiforme model. Hum Gene Ther 8: 1073-1085, 1997.
26. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Martin Kast W, Deleo AB and Lotze MT: Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nature Med 1: 1297-1302, 1995.
27. Gong J, Chen D, Kashiwaba M and Kufe D: Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nature Med 3: 558-561, 1997.